{"id":316,"date":"2022-03-16T16:55:07","date_gmt":"2022-03-16T20:55:07","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=316"},"modified":"2022-03-16T16:55:25","modified_gmt":"2022-03-16T20:55:25","slug":"fda-final-guidance-on-initiating-voluntary-recalls-be-recall-ready","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2022\/03\/16\/fda-final-guidance-on-initiating-voluntary-recalls-be-recall-ready\/","title":{"rendered":"FDA Final Guidance on Initiating Voluntary Recalls: Be “Recall Ready”"},"content":{"rendered":"

On March 4, 2022, FDA issued a final guidance to industry and FDA staff regarding the initiation of voluntary recalls under 21 CFR part 7, subpart C. The guidance applies to voluntary recalls of products subject to FDA\u2019s jurisdiction, including any:<\/p>\n

    \n
  1. \n
      \n
    1. Food, drug and device (human or animal use);<\/li>\n
    2. Cosmetic and biological product (human use);<\/li>\n
    3. Tobacco product;<\/li>\n
    4. Item subject to a quarantine regulation under 21 CFR part 1240; and<\/li>\n
    5. Devices that are electronic products regulated as radiology devices (subject to 21 CFR part 892) but not electronic products subject to 21 CFR parts 1003 and 1004.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n

      In short, the final guidance clarifies FDA\u2019s recommendations on how a firm should be prepared to facilitate the timely initiation of voluntary recalls, steps a firm should take if there is an indication of a problem with a distributed product and how to initiate voluntary recalls. The final guidance also explains how FDA works with firms to initiate a voluntary recall.<\/p>\n

      To read the full text of this Duane Morris Alert, please visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

      On March 4, 2022, FDA issued a final guidance to industry and FDA staff regarding the initiation of voluntary recalls under 21 CFR part 7, subpart C. The guidance applies to voluntary recalls of products subject to FDA\u2019s jurisdiction, including any: Food, drug and device (human or animal use); Cosmetic and biological product (human use); … <\/p>\n

      Continue reading “FDA Final Guidance on Initiating Voluntary Recalls: Be “Recall Ready””<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[605,29,65,209,298,119,369],"ppma_author":[521],"class_list":["post-316","post","type-post","status-publish","format-standard","hentry","category-general","tag-coleen-hill","tag-fda","tag-final-guidance","tag-frederick-ball","tag-patrick-gallagher","tag-rick-ball","tag-voluntary-recall"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=316"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/316\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=316"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}